Triad Life Sciences, a Memphis, Tenn.-based biotech company, raised AUS$25m funding round.
The convertible note placement was led by Cannacord Genuity.
The company intends to use the funds for its US sales force expansion plans, R&D activities, and general working capital needs. Triad now plans to move forward with a listing on the Australian Securities Exchange (ASX) in the coming months.
Led by CEO Russ Olsen, Triad Life Sciences is a biotech company focused on developing and commercializing biomaterials for treating complex surgical and chronic wounds. Triad recently received FDA clearance to market InnovaMatrix™, a next generation extracellular matrix (ECM) wound care device.
FinSMEs
30/08/2021